Charles River Laboratories (CRL) Cash Flow Statement

Click line-items for a historical chart and %

Net income	111.14M
Less: Loss from discontinued operations	328K
Income from continuing operations	110.81M
Depreciation and amortization	91.12M
Non-cash compensation	32.65M
Amortization of debt issuance costs and discounts	2.33M
Other, net	4.03M
Trade receivables	-43.26M
Inventories	-4.35M
Other assets	-5.7M
Accounts payable	17.18M
Accrued compensation	8.16M
Deferred revenue	2.17M
Accrued liabilities	-15.18M
Taxes payable and prepaid taxes
Other liabilities	617K
Net cash provided by operating activities	186.12M
Capital expenditures	-29.61M
Purchases of investments	-20.28M
Proceeds from sale of investments	28.27M
Other, net	3.79M
Net cash provided by (used in) investing activities	-615.43M
Proceeds from long-term debt and revolving credit agreement
Payments on long-term debt, capital lease obligation and revolving credit agreement
Proceeds from exercises of stock options
Purchase of treasury stock and Accelerated Stock Repurchase Program	-12.23M
Other, net	4.98M
Net cash used in financing activities	414.19M
Net cash used in operating activities	-1.43M
Net cash provided by investing activities
Net cash provided by (used in) discontinued operations
Effect of exchange rate changes on cash and cash equivalents	4.33M
Net change in cash and cash equivalents	-12.23M
Cash and cash equivalents, beginning of period	117.95M
Cash and cash equivalents, end of period	105.72M
Capitalized interest

Entities mentioned with CRL

View All Entities